Crispr Therapeutics AG vs Old Dominion Freight Line Inc — how do they compare? Crispr Therapeutics AG trades at $51.11 (market cap $4.88B), while Old Dominion Freight Line Inc trades at $183.23 (market cap $37.68B). The key difference: Old Dominion Freight Line Inc is far larger — about 7.7× Crispr Therapeutics AG's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Old Dominion Freight Line Inc for 76 Days on average.
| CRSP | ODFL | |
|---|---|---|
Market Cap | $4.88B | $37.68B |
Volume | 2,861,747 | 1,550,104 |
Sector | Health | Industrials |
52-Week High | $74.92 | $248.73 |
52-Week Low | $44.34 | $126.29 |
Typical Hold Time | 77 Days | 76 Days |
Enterprise Value | $3.30B | $37.42B |
Dividend Yield | — | 0.64% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Old Dominion Freight Line (ODFL) trades at $175.61, down 1.35% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.68 exceeding the $1.54 estimate. Revenue for 2025 was $5.50B, with a net income margin of 19.44%. A 4.9% general rate increase effective October 5, 2026, aims to support service investments amid cost pressures.
ODFL presents a mixed outlook; analyst consensus is a Buy with a $230.93 price target, implying significant upside, but technical indicators suggest near-term pressure. Risks include freight demand volatility and high valuation multiples. The stock's investment case hinges on execution of rate increases and sustained operational efficiency in a competitive trucking sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →